- Concomitant use of any anti-cancer therapy, except for continued use of luteinizing hormone-releasing hormone (LHRH) agonists or antiandrogens, or bisphosphonates or steroids initiated at least 4 weeks prior to study entry;

- Concomitant use of any investigational agent, including PC-SPES;

- Use of any investigational agent within 4 weeks of study entry;

- Concomitant use of warfarin (due to a potential drug-to-drug interaction with depsipeptide);

- Major surgery within 2 weeks of study entry;

- Prior treatment with chemotherapy;

- Patients with known cardiac abnormalities such as:

- Congenital long QT syndrome;

- QTc interval > 480 milliseconds;

- Patients who have had a myocardial infarction within 12 months of study entry;

- Patients who have a history of coronary artery disease (CAD) e.g., angina Canadian Class II IV (see Appendix K). In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;

- Patients with an ECG recorded at screening showing evidence of cardiac ischemia (ST depression of ≥2 mm). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.